Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

by divibasicbldev | Sep 26, 2024 | Press Releases

— Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle — — No treatment-related adverse events (TRAEs) or dose-limiting toxicities...

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

by divibasicbldev | Sep 9, 2024 | Press Releases

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment...

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

by divibasicbldev | Sep 3, 2024 | Press Releases

Dr. Brown is a world-leading expert in Neurofibromatosis (NF) and the Director of the Neurofibromatosis clinic at The Mount Sinai Hospital, NYMIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the...

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

by divibasicbldev | Aug 28, 2024 | Press Releases

SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK...

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

by divibasicbldev | Jun 13, 2024 | Press Releases

— On track for initial interim safety and PK data release in Q3 2024 –MIAMI, June 13, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...